Physician profile
Daniel C Barry
NPI 1104877885
$1,404.56
in general payments reported to CMS, 2019-2025
12 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $411 · 2023: $113 · 2024: $347 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $895.61 | 2021-2025 | |
| Janssen Biotech, INC. | $104.36 | 2022-2025 | Tremfya |
| Novo Nordisk INC | $99.50 | 2021-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $69.63 | 2024 | Benlysta |
| Ucb, INC. | $51.39 | 2024-2025 | Bimzelx, Cimzia |
| Smith+Nephew, INC. | $46.70 | 2023 | Stravix, Oasis, Grafix |
| Dexcom, INC. | $37.56 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $24.85 | 2022 | |
| Amgen INC. | $22.02 | 2025 | Evenity |
| Tandem Diabetes Care, INC. | $19.45 | 2022 | |
| Lilly USA, LLC | $18.78 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.71 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.